Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 20Gastrointestinal 5Lymphoid 3Genitourinary 3Gynecologic 2Dermatologic 2CNS 2Breast 2Thoracic 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Endocrine 1

Conditions

Neuroendocrine Tumors 5Carcinoma, Neuroendocrine 5Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Somatostatinoma 2Neoplasm Metastasis 2Insulinoma 2Glucagonoma 2Gastrinoma 2Carcinoma, Islet Cell 2Carcinoid Tumor 2Adenoma, Islet Cell 2Vipoma 1Sarcoma 1Pancreatic Neoplasms 1Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Metastatic Gastrointestinal Carcinoid Tumor 1Mesothelioma, Malignant 1Lymphoma 1Lung Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma 1Adrenocortical Carcinoma 1Adenocarcinoma, Mucinous 1

Interventions

Fluorodeoxyglucose F18 3Doxorubicin 3Cyclophosphamide 3surufatinib 2fludarabine 2entrectinib 2Radiotherapy 2Nivolumab 2Ifosfamide 2Filgrastim 2Drug Therapy 2Cisplatin 2tivozanib 1tislelizumab 1tipifarnib 1selpercatinib 1romidepsin 1repotrectinib 1regorafenib 1pembrolizumab 1milademetan 1ganitumab 1fludarabine phosphate 1entinostat 1dostarlimab 1conatumumab 1cixutumumab 1cabozantinib 1atezolizumab 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Bevacizumab × Endocrine × Clear all
NCT01327612 2021-02-21

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Amgen

Phase 2 Completed
12 enrolled 21 charts
EndocrineGastrointestinalLymphoidSarcomaThoracic

Carcinoid Tumor, Carcinoma, Non-Small-Cell Lung, Lymphoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡